Urgent.News

What's breaking now, across thousands of outlets.

Science

Nvidia's Groq acquihire is on the DOJ's radar, but it's already too late

Even if regulators did somehow unwind the $20B deal, there's a growing list of alternatives ready to take Groq's place, no merger required

Nvidia's Groq acquihire is on the DOJ's radar, but it's already too late

Nvidia's $20 billion acquisition of Groq, an AI accelerator startup, has drawn the attention of the US Department of Justice (DOJ). While the deal technically left Groq's core business intact, it was designed to evade regulators. The DOJ's probe questions whether Nvidia's acquisition, which stripped Groq of its engineering team, harmed competition.

Nvidia acquired Groq's mature silicon and talent necessary for continued development. Groq's SRAM-heavy dataflow accelerators enabled LLM inference up to thousands of tokens per second, outperforming GPU-based systems. Together, Nvidia's LPX racks and Groq's accelerators deliver optimal performance across various inference workloads. However, other companies like Cerebras, SambaNova, and d-Matrix are developing similar disaggregated compute architectures.

Critics argue that Nvidia's acquisition of Groq, though not a traditional merger, effectively bought the startup's technology and talent. While the DOJ may be able to undo the deal, it is likely too late to prevent the potential negative impact on competition. Even if the DOJ succeeds in blocking the acquisition, Nvidia's ecosystem, centered around its networking business, could still accommodate alternatives.

Written by urgent.news from The Register Science's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at theregister.com →

More in Science

Scientists find Ozempic may slow aging itself

Semaglutide helped older healthy mice live longer while improving memory, muscle function, blood sugar control, and several biological signs of aging. Its effects went beyond those seen with calorie restriction, raising the possibility that GLP-1 drugs could tap into a separate biological pathway linked to longevity.

More from Saturday 12 September →